Percutaneous fine needle aspiration biopsy in clinical pancreas transplantation
| Autor: | Merle L. Greenberg, M J Earl, Jeremy R. Chapman, Richard D. M. Allen, Grierson Jm |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Kidney
medicine.medical_specialty Percutaneous medicine.diagnostic_test business.industry medicine.medical_treatment Ultrasound Pancreas allograft Pancreas transplantation Pathology and Forensic Medicine Surgery Fine-needle aspiration medicine.anatomical_structure Biopsy medicine Radiology Pancreas business |
| Zdroj: | Pathology. 24:29 |
| ISSN: | 0031-3025 |
| DOI: | 10.1016/s0031-3025(16)35988-8 |
| Popis: | Lack of reliable and specific independent monitoring of pancreas allograft function prompted evaluation of fine needle aspiration biopsy (FNAB) as a safe and reliable method for determining cellular rejection. Ultrasound localised 22G FNAB and 20G needle core biopsy (NCB) were performed between 6 and 90 days. Twenty patients received combined kidney and pancreas transplants and one patient, a pancreas alone. There were no significant biopsy complications. Cytocentrifuged aspirates were considered adequate if 10 or more clusters of pancreas acinar cells were present. Thirty four of 52 (65%) attempted FNAB were satisfactory for assessment. Based on a previous canine pancreas allograft model, a diagnosis of rejection was made when the total corrected increment (TCI) was > 2.6, provided that more than 50% of this value comprised blasts, or blasts and macrophages. Concurrent FNAB and NCB were assessable on 22 of 35 occasions. Compared to NCB, the sensitivity and specificity of FNAB for a diagnosis of rejection were 83.3% and 87.5% respectively. Graft survival, followed from 3 to 46 months for pancreas and kidney was 85% and 95% respectively. In conclusion, FNAB was shown to be a safe and specific method of following intragraft cellular events in the pancreas. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|